Meg Tirrell

Meg Tirrell is a seasoned medical correspondent with extensive experience in reporting on health and wellness stories across various platforms. She currently works for CNN's award-winning Health unit, where she covers a wide range of health topics including new medicines for Alzheimer's disease, cancer, and rare diseases. Prior to joining CNN, Tirrell served as CNBC's senior health and science reporter, where she reported on public health emergencies such as Ebola, Zika, and COVID-19. She has also covered the drug industry's accountability for the opioid epidemic and market failures leading to life-threatening drug shortages. Tirrell holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.

Biography:  https://www.cnn.com/profiles/meg-tirrell

96%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

98%

Examples:

No current examples available.

Deceptions

88%

Examples:

  • The implications are profound.
  • We have not encountered a drug with such a breadth of heart benefits.

Recent Articles

New Weight Loss Drug Liraglutide Shows Promise in Slowing Cognitive Decline and Reducing Brain Shrinkage in Alzheimer's Patients: Potential Neuroprotective Effects

New Weight Loss Drug Liraglutide Shows Promise in Slowing Cognitive Decline and Reducing Brain Shrinkage in Alzheimer's Patients: Potential Neuroprotective Effects

Broke On: Tuesday, 30 July 2024 Liraglutide, a weight loss drug similar to Ozempic, shows potential in slowing cognitive decline and reducing brain shrinkage in patients with mild Alzheimer's disease according to recent research. The drug may have neuroprotective effects beyond managing diabetes and weight loss. Phase 3 clinical trials are expected to begin soon with potential FDA approval happening as early as next year.
New Weight Loss Drug Semaglutide Reduces Cardiovascular Risk by 20%: Preliminary Findings from Two Studies

New Weight Loss Drug Semaglutide Reduces Cardiovascular Risk by 20%: Preliminary Findings from Two Studies

Broke On: Monday, 13 May 2024 A major medical breakthrough: Semaglutide, a weight loss drug, reduces heart attack, stroke, or death due to cardiovascular disease risk by 20% according to two studies presented at the European Congress of Obesity. The medication's potential cardiovascular benefits could make it a game-changer for treating heart conditions in millions across the UK.